Results 1 to 10 of about 2,532,507 (339)

Primary cytoreductive surgery or interval cytoreductive surgery

Taiwanese Journal of Obstetrics & Gynecology
Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
doaj   +4 more sources

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

World Journal of Surgical Oncology, 2022
Background Cytoreductive surgery followed by systemic chemotherapy is the standard of treatment in advanced ovarian cancer where feasible. Neoadjuvant chemotherapy (NACT) followed by surgery is applicable where upfront cytoreductive surgery is not ...
Ester Miralpeix, Josep-Maria Sole-Sedeno, Cristina Rodriguez-Cosmen, Alvaro Taus, Maria-Dolors Muns, Berta Fabregó, Gemma Mancebo   +6 more
doaj   +2 more sources

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study [PDF]

Obstetrics & Gynecology Science, 2020
ObjectiveThe primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine the perioperative
Semiramis L. Carbajal-Mamani, David Schweer, Merry J. Markham, Ashwini K. Esnakula, Joseph R. Grajo, Jacqueline C. Castagno, Joel Cardenas-Goicoechea   +6 more
doaj   +2 more sources

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Frontiers in Oncology, 2022
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in
Eelco de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou   +2 more
doaj   +2 more sources

Cytoreductive surgery for ovarian carcinoma [PDF]

Journal of British Surgery, 1990
Nigel Scott, P F Schofield
openalex   +4 more sources

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis in the Elderly [PDF]

International Journal of Surgical Oncology, 2014
Background. The combined treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a rigorous surgical treatment, most suitable for young and good performance status patients. We evaluated the outcomes of elderly patients undergoing CRS and HIPEC for peritoneal carcinomatosis with careful ...
John Spiliotis, Evgenia Halkia, V. A. Boumis, Dimitra Vassiliadou, Alexandra Pagoulatou, Elias Efstathiou   +5 more
openalex   +5 more sources

Cytoreductive surgery for men with metastatic prostate cancer

Prostate International, 2016
Background: Cytoreductive surgery for metastatic prostate cancer is an emerging area of interest with a potential upside that includes local control, delayed initiation of hormone therapy, and possibly improved cancer specific survival.
Nikolas Katelaris, Declan Murphy, Nathan Lawrentschuk, Athos Katelaris, Daniel Moon   +4 more
doaj   +5 more sources

Comparison of Cytoreductive Surgery and Resection of Isolated Peritoneal Metastases in Patients with Peritoneal Metastases from Colorectal Cancer: A Retrospective Study

Journal of the Anus, Rectum and Colon, 2023
Objectives: This study aimed to compare the short and long-term outcomes of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy and resection of isolated peritoneal metastases in patients with peritoneal metastases from colorectal cancer
Shinya Yoshida, Yasuyuki Kamada, Koya Hida, Kazuyuki Okada, Kazutaka Obama, Satoshi Morita, Toshiyuki Kitai, Yutaka Yonemura   +7 more
doaj   +1 more source

Enhanced Recovery after Surgery (ERAS) Program for Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery with or without HIPEC: A Systematic Review and a Meta-Analysis

Cancers, 2023
Simple Summary Cytoreductive surgery and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) represent a promising treatment strategy for the management of selected cases of peritoneal cancer, but it’s still burdened by significant morbidity and prolonged ...
M. Robella, M. Tonello, P. Berchialla, V. Sciannameo, Alba Ilari Civit, A. Sommariva, C. Sassaroli, A. di Giorgio, R. Gelmini, V. Ghirardi, F. Roviello, F. Carboni, P. Lippolis, S. Kusamura, M. Vaira   +14 more
semanticscholar   +1 more source

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer

JAMA Surgery, 2022
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer?
M. Lim, Suk-Joon Chang, Boram Park, H. Yoo, C. Yoo, B. Nam, Sang-Yoon Park   +6 more
semanticscholar   +1 more source